Compare HCAT & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAT | MBOT |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.0M | 114.9M |
| IPO Year | 2019 | 2000 |
| Metric | HCAT | MBOT |
|---|---|---|
| Price | $1.90 | $1.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | $2.53 | ★ $7.50 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $311,136,000.00 | $116,887.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $119.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1.48 | N/A |
| 52 Week Low | $0.96 | $1.60 |
| 52 Week High | $4.29 | $4.62 |
| Indicator | HCAT | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 73.37 | 42.52 |
| Support Level | $1.62 | $1.65 |
| Resistance Level | $2.00 | $2.21 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 67.96 | 36.87 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.